Getting older with chronic temporal lobe epilepsy: What memory profile?

Samson, Séverine; Moncomble, C.; Méré, Marie; Vasseur, R.; Dupont, Sophie

doi:10.1016/j.neurol.2020.04.011

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that ageing worsens verbal episodic memory performances and executive tasks. This finding has already been reported in both healthy volunteers [56] and PWE [31,57]. Even if these results may highlight a normal ageing phenomenon, we did not find a worsening of another cognitive domains with age reinforcing the implication of temporal lobe neocortex in declarative memory and executive functions.…”

Section: Agesupporting

confidence: 85%

Distinctive neuropsychological profiles of lateral temporal lobe epilepsy

Longo

Houot²,

Herlin³

et al. 2021

Epilepsy & Behavior

View full text Add to dashboard Cite

Section: Agesupporting

confidence: 85%

Distinctive neuropsychological profiles of lateral temporal lobe epilepsy

Longo

Houot²,

Herlin³

et al. 2021

Epilepsy & Behavior

View full text Add to dashboard Cite

“…The main effects of socio-demographic factors on cognitive scores (Table S1) were known and expected: (i) a strong correlation between education level and cognitive performance [37,38]; (ii) a correlation between aging and worsening in several cognitive domains: verbal episodic memory, short-term memory, executive and language functions [39][40][41][42][43][44][45]; (iii) better performance in women with MTLE-HS in constructive and visual skills and verbal memory tests [46]; (iv) an association of poorer verbal memory with younger age at epilepsy onset [47]; and (v) pronounced impairment of verbal memory in patients with left-but not right-sided MTLE [48].…”

Section: Effect Of Unmodifiable Parametersmentioning

confidence: 99%

Cognitive effect of antiseizure medications in medial temporal lobe epilepsy

Dusanter,

Houot,

Mere

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeThe specific effects of antiseizure medications (ASMs) on cognition are a rich field of study, with many ongoing questions. The aim of this study was to evaluate these effects in a homogeneous group of patients with epilepsy to guide clinicians to choose the most appropriate medications.MethodsWe retrospectively identified 287 refractory patients with medial temporal lobe epilepsy associated with hippocampal sclerosis. Scores measuring general cognition (global, verbal and performance IQ), working memory, episodic memory, executive functions, and language abilities were correlated with ASM type, number, dosage and generation (old vs. new). We also assessed non‐modifiable factors affecting cognition, such as demographics and epilepsy‐related factors.ResultsKey parameters were total number of ASMs and specific medications, especially topiramate (TPM) and sodium valproate (VPA). Four cognitive profiles of the ASMs were identified: (i) drugs with an overall detrimental effect on cognition (TPM, VPA); (ii) drugs with negative effects on specific areas: verbal memory and language skills (carbamazepine), and language functions (zonisamide); (iii) drugs affecting a single function in a specific and limited area: visual denomination (oxcarbazepine, lacosamide); and (iv) drugs without documented cognitive side effects. Non‐modifiable factors such as age at testing, age at seizure onset, and history of febrile seizures also influenced cognition and were notably influenced by total number of ASMs.ConclusionWe conclude that ASMs significantly impact cognition. Key parameters were total number of ASMs and specific medications, especially TPM and VPA. These results should lead to a reduction in the number of drugs received and the avoidance of medications with unfavorable cognitive profiles.

show abstract

“…Manifesting as recurrent and unprovoked focal seizures, the persistent and frequent epileptic discharges can result in substantial damage to intelligence and cognitive function, significantly impacting the patient's quality of life [2,3]. Furthermore, given the unpredictable nature of this condition, a majority of patients experience varying degrees of anxiety and depressive emotions, imposing a considerable psychological burden [4]. Effe-ctively managing temporal lobe epilepsy is, therefore, a critical challenge that necessitates attention.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of levetiracetam combined with oxcarbazepine in the treatment of adults with temporal lobe epilepsy and its impact on memory and cognitive function

2024

Am J Transl Res

View full text Add to dashboard Cite

Objective: To explore the effect of levetiracetam combined with oxcarbazepine on the memory and cognitive function of adult patients with temporal lobe epilepsy. Methods: This retrospective analysis included 91 adult patients with temporal lobe epilepsy treated at Xianyang Hospital from June 2020 to December 2022. Based on their medication regimen, patients were categorized into an observation group (n=51) receiving levetiracetam plus oxcarbazepine and a control group (n=40) receiving only levetiracetam. Both groups underwent 3 months of continuous treatment. Therapeutic efficacy, pre-and post-treatment memory function (assessed using the Clinical Memory Scale, CMS), cognitive function (evaluated with the Wechsler Adult Intelligence Scale-Revised in China, WAISRC), anxiety and depression levels (measured by the Hamilton Anxiety Scale, HAMA, and Hamilton Depression Scale, HAMD), as well as adverse reactions, were compared between the two groups. Independent factors influencing treatment efficacy were also analyzed. Results: CMS and WAISRC scores significantly increased in both groups after treatment (both P=0.001), with the observation group showing more significant improvements than the control group (P=0.001). The improvements in HAMA and HAMD scores in the observation group were significantly better than the control group (all P<0.001). Adverse reaction occurrence showed no significant difference between the two groups (P>0.05). Prognostic analysis identified seizure frequency and treatment regimen as independent factors influencing efficacy. Conclusion: Levetiracetam combined with oxcarbazepine effectively improves cognitive dysfunction in adults with temporal lobe epilepsy, with superior efficacy to levetiracetam alone, and good safety.

show abstract

Getting older with chronic temporal lobe epilepsy: What memory profile?

Cited by 6 publications

References 25 publications

Distinctive neuropsychological profiles of lateral temporal lobe epilepsy

Distinctive neuropsychological profiles of lateral temporal lobe epilepsy

Cognitive effect of antiseizure medications in medial temporal lobe epilepsy

Efficacy of levetiracetam combined with oxcarbazepine in the treatment of adults with temporal lobe epilepsy and its impact on memory and cognitive function

Contact Info

Product

Resources

About